383 related articles for article (PubMed ID: 24433482)
21. Ameliorating the in vivo antimalarial efficacy of artemether using nanostructured lipid carriers.
Vanka R; Kuppusamy G; Praveen Kumar S; Baruah UK; Karri VVSR; Pandey V; Babu PP
J Microencapsul; 2018 Mar; 35(2):121-136. PubMed ID: 29448884
[TBL] [Abstract][Full Text] [Related]
22. PPARγ agonists improve survival and neurocognitive outcomes in experimental cerebral malaria and induce neuroprotective pathways in human malaria.
Serghides L; McDonald CR; Lu Z; Friedel M; Cui C; Ho KT; Mount HT; Sled JG; Kain KC
PLoS Pathog; 2014 Mar; 10(3):e1003980. PubMed ID: 24603727
[TBL] [Abstract][Full Text] [Related]
23. Synthesis of artemiside and its effects in combination with conventional drugs against severe murine malaria.
Guo J; Guiguemde AW; Bentura-Marciano A; Clark J; Haynes RK; Chan WC; Wong HN; Hunt NH; Guy RK; Golenser J
Antimicrob Agents Chemother; 2012 Jan; 56(1):163-73. PubMed ID: 22006004
[TBL] [Abstract][Full Text] [Related]
24. Glucagon-like peptide-1 analogue, liraglutide, in experimental cerebral malaria: implications for the role of oxidative stress in cerebral malaria.
DellaValle B; Hempel C; Staalsoe T; Johansen FF; Kurtzhals JA
Malar J; 2016 Aug; 15(1):427. PubMed ID: 27554094
[TBL] [Abstract][Full Text] [Related]
25. Exogenous nitric oxide decreases brain vascular inflammation, leakage and venular resistance during Plasmodium berghei ANKA infection in mice.
Zanini GM; Cabrales P; Barkho W; Frangos JA; Carvalho LJ
J Neuroinflammation; 2011 Jun; 8():66. PubMed ID: 21649904
[TBL] [Abstract][Full Text] [Related]
26. IL-33 receptor ST2 regulates the cognitive impairments associated with experimental cerebral malaria.
Reverchon F; Mortaud S; Sivoyon M; Maillet I; Laugeray A; Palomo J; Montécot C; Herzine A; Meme S; Meme W; Erard F; Ryffel B; Menuet A; Quesniaux VFJ
PLoS Pathog; 2017 Apr; 13(4):e1006322. PubMed ID: 28448579
[TBL] [Abstract][Full Text] [Related]
27. Neuregulin-1 inhibits neuroinflammatory responses in a rat model of organophosphate-nerve agent-induced delayed neuronal injury.
Li Y; Lein PJ; Ford GD; Liu C; Stovall KC; White TE; Bruun DA; Tewolde T; Gates AS; Distel TJ; Surles-Zeigler MC; Ford BD
J Neuroinflammation; 2015 Apr; 12():64. PubMed ID: 25880399
[TBL] [Abstract][Full Text] [Related]
28. Emerging avenues for the management of cerebral malaria.
Das N; Prabhu P
J Pharm Pharmacol; 2022 Jun; 74(6):800-811. PubMed ID: 35429389
[TBL] [Abstract][Full Text] [Related]
29. Synthetic oleanane triterpenoids enhance blood brain barrier integrity and improve survival in experimental cerebral malaria.
Crowley VM; Ayi K; Lu Z; Liby KT; Sporn M; Kain KC
Malar J; 2017 Nov; 16(1):463. PubMed ID: 29137631
[TBL] [Abstract][Full Text] [Related]
30. Neuroimmunological blood brain barrier opening in experimental cerebral malaria.
Nacer A; Movila A; Baer K; Mikolajczak SA; Kappe SH; Frevert U
PLoS Pathog; 2012; 8(10):e1002982. PubMed ID: 23133375
[TBL] [Abstract][Full Text] [Related]
31. Lambda-carrageenan treatment exacerbates the severity of cerebral malaria caused by Plasmodium berghei ANKA in BALB/c mice.
Recuenco FC; Takano R; Chiba S; Sugi T; Takemae H; Murakoshi F; Ishiwa A; Inomata A; Horimoto T; Kobayashi Y; Horiuchi N; Kato K
Malar J; 2014 Dec; 13():487. PubMed ID: 25495520
[TBL] [Abstract][Full Text] [Related]
32. Suppressor of cytokine signaling 2 modulates the immune response profile and development of experimental cerebral malaria.
Brant F; Miranda AS; Esper L; Gualdrón-López M; Cisalpino D; de Souza DDG; Rachid MA; Tanowitz HB; Teixeira MM; Teixeira AL; Machado FS
Brain Behav Immun; 2016 May; 54():73-85. PubMed ID: 26765997
[TBL] [Abstract][Full Text] [Related]
33. Effects of anti-tau immunotherapy on reactive microgliosis, cerebral endotheliopathy, and cognitive function in an experimental model of cerebral malaria.
Akide Ndunge OB; Shikani HJ; Dai M; Freeman BD; Desruisseaux MS
J Neurochem; 2023 Nov; 167(3):441-460. PubMed ID: 37814468
[TBL] [Abstract][Full Text] [Related]
34. Efficacy and safety evaluation of a novel trioxaquine in the management of cerebral malaria in a mouse model.
Odhiambo OC; Wamakima HN; Magoma GN; Kirira PG; Malala BJ; Kimani FT; Muregi FW
Malar J; 2017 Jul; 16(1):268. PubMed ID: 28673299
[TBL] [Abstract][Full Text] [Related]
35. Nanostructured lipid carriers of artemether-lumefantrine combination for intravenous therapy of cerebral malaria.
Prabhu P; Suryavanshi S; Pathak S; Patra A; Sharma S; Patravale V
Int J Pharm; 2016 Nov; 513(1-2):504-517. PubMed ID: 27596113
[TBL] [Abstract][Full Text] [Related]
36. Young Sprague Dawley rats infected by Plasmodium berghei: A relevant experimental model to study cerebral malaria.
Keita Alassane S; Nicolau-Travers ML; Menard S; Andreoletti O; Cambus JP; Gaudre N; Wlodarczyk M; Blanchard N; Berry A; Abbes S; Colongo D; Faye B; Augereau JM; Lacroux C; Iriart X; Benoit-Vical F
PLoS One; 2017; 12(7):e0181300. PubMed ID: 28742109
[TBL] [Abstract][Full Text] [Related]
37. Perillyl alcohol exhibits in vitro inhibitory activity against Plasmodium falciparum and protects against experimental cerebral malaria.
Rodriguez AAM; Carvalho LJM; Kimura EA; Katzin AM
Int J Antimicrob Agents; 2018 Mar; 51(3):370-377. PubMed ID: 28843818
[TBL] [Abstract][Full Text] [Related]
38.
Elphinstone RE; Besla R; Shikatani EA; Lu Z; Hausladen A; Davies M; Robbins CS; Husain M; Stamler JS; Kain KC
Infect Immun; 2017 Sep; 85(9):. PubMed ID: 28674030
[TBL] [Abstract][Full Text] [Related]
39. Minocycline prevents cerebral malaria, confers neuroprotection and increases survivability of mice during Plasmodium berghei ANKA infection.
Apoorv TS; Babu PP
Cytokine; 2017 Feb; 90():113-123. PubMed ID: 27865203
[TBL] [Abstract][Full Text] [Related]
40. Establishment of a murine model of cerebral malaria in KunMing mice infected with Plasmodium berghei ANKA.
Ding Y; Xu W; Zhou T; Liu T; Zheng H; Fu Y
Parasitology; 2016 Oct; 143(12):1672-80. PubMed ID: 27574013
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
